Abstract
Peanut immunotherapy is poised to offer a significant shift in paradigms of care for patients with peanut allergy, and both oral and epicutaneous forms of therapy may be approved in the coming years.1,2 These new products may include a commercial peanut oral immunotherapy (POIT) treatment (AR101; Aimmune Therapeutics) as well as an epicutaneous peanut immunotherapy (EPIT) patch (Viaskin peanut; DBV Technologies). Neither therapy is curative (ie, creates a lasting tolerance allowing ad libitum peanut consumption), although both may offer some increase in the amount of peanut an individual can tolerate before reacting (or the amount at which a reaction will occur) of between 300 and 1000 mg of peanut protein (estimated to reduce the risk of reaction from accidental exposure from products with precautionary labeling by 95% to 99% and, at the upper ranges, protect from a small bite of a peanut-containing product) as well as some possible attenuation of the severity of a reaction on peanut exposure.3-6 However, patients treated with these therapies must still follow strict peanut avoidance and carry emergency medications. How these therapies may ultimately be used in the treatment of peanut allergy is incompletely understood.7 Both therapies have risks of adverse events, including anaphylaxis related to the treatment itself, although the degree to which patients may accept this as a trade-off is unknown.8 To better understand the potential health benefits and economic outcomes (eg, relative costs and value) of these commercial food allergy therapies, we performed Markov modeling with microsimulation and cost-effectiveness analysis.

This publication has 35 references indexed in Scilit: